These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 4536364)

  • 1. The sickling process in relation to clinical manifestations.
    Bellingham AJ
    J Clin Pathol Suppl (R Coll Pathol); 1974; 8():23-5. PubMed ID: 4536364
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Understanding antisickling agents and the sickling process.
    Godwin M; Baysinger M
    Nurs Clin North Am; 1983 Mar; 18(1):207-14. PubMed ID: 6550864
    [No Abstract]   [Full Text] [Related]  

  • 3. Identification of 2-imidazolines as anti-sickling agents.
    Chang H; Ewert SM; Nagel RL
    Mol Pharmacol; 1983 May; 23(3):731-4. PubMed ID: 6865916
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overview of pathophysiology and rationale for treatment of sickle cell anemia.
    Rodgers GP
    Semin Hematol; 1997 Jul; 34(3 Suppl 3):2-7. PubMed ID: 9317195
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Established and experimental treatments for sickle cell disease.
    De Franceschi L; Corrocher R
    Haematologica; 2004 Mar; 89(3):348-56. PubMed ID: 15020275
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The mechanism of action of two anti-sickling agents: sodium cyanate and glyceraldehyde.
    Manning JM; Acharya AS
    Am J Pediatr Hematol Oncol; 1984; 6(1):51-4. PubMed ID: 6711764
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Viscosity and filtrability measurements of sickle-cell suspensions in the development of anti-sickling drugs.
    Ohnishi ST
    Blood Cells; 1982; 8(1):79-87. PubMed ID: 7115980
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hydroxyurea in the treatment of sickle-cell anemia.
    Howard LW; Kennedy LD
    Ann Pharmacother; 1997 Nov; 31(11):1393-6. PubMed ID: 9391697
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A new approach to the treatment of sickle cell anemia.
    Milosz A; Settle W
    Res Commun Chem Pathol Pharmacol; 1975 Sep; 12(1):137-46. PubMed ID: 1188180
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hydroxyurea for children with sickle cell disease.
    Heeney MM; Ware RE
    Pediatr Clin North Am; 2008 Apr; 55(2):483-501, x. PubMed ID: 18381097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New developments in anti-sickling agents: can drugs directly prevent the polymerization of sickle haemoglobin in vivo?
    Oder E; Safo MK; Abdulmalik O; Kato GJ
    Br J Haematol; 2016 Oct; 175(1):24-30. PubMed ID: 27605087
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitative prediction of erythrocyte sickling for the development of advanced sickle cell therapies.
    Lu L; Li Z; Li H; Li X; Vekilov PG; Karniadakis GE
    Sci Adv; 2019 Aug; 5(8):eaax3905. PubMed ID: 31457104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of sickle cell disease by increasing oxygen affinity of hemoglobin.
    Henry ER; Metaferia B; Li Q; Harper J; Best RB; Glass KE; Cellmer T; Dunkelberger EB; Conrey A; Thein SL; Bunn HF; Eaton WA
    Blood; 2021 Sep; 138(13):1172-1181. PubMed ID: 34197597
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of carbon dioxide and pH variations in vitro on blood respiratory functions, red blood cell volume, transmembrane pH gradients, and sickling in sickle cell anemia.
    Ueda Y; Bookchin RM
    J Lab Clin Med; 1984 Aug; 104(2):146-59. PubMed ID: 6431043
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of the antisickling compound GBT1118 on the permeability of red blood cells from patients with sickle cell anemia.
    Al Balushi H; Dufu K; Rees DC; Brewin JN; Hannemann A; Oksenberg D; Lu DC; Gibson JS
    Physiol Rep; 2019 Mar; 7(6):e14027. PubMed ID: 30916477
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New advances in the treatment of sickle cell disease: focus on perioperative significance.
    Dix HM
    AANA J; 2001 Aug; 69(4):281-6. PubMed ID: 11759366
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New antisickling agents.
    Labie D
    Haematologia (Budap); 1983; 16(1-4):105-8. PubMed ID: 6679483
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hydroxyurea therapy: improving the lives of patients with sickle cell disease.
    Anderson N
    Pediatr Nurs; 2006; 32(6):541-3. PubMed ID: 17256291
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of cetiedil on monovalent cation permeability in the erythrocyte: an explanation for the efficacy of cetiedil in the treatment of sickle cell anemia.
    Berkowitz LR; Orringer EP
    Blood Cells; 1982; 8(2):283-8. PubMed ID: 7159752
    [TBL] [Abstract][Full Text] [Related]  

  • 20. VZHE-039, a novel antisickling agent that prevents erythrocyte sickling under both hypoxic and anoxic conditions.
    Abdulmalik O; Pagare PP; Huang B; Xu GG; Ghatge MS; Xu X; Chen Q; Anabaraonye N; Musayev FN; Omar AM; Venitz J; Zhang Y; Safo MK
    Sci Rep; 2020 Nov; 10(1):20277. PubMed ID: 33219275
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.